Surgery – Diagnostic testing
Reexamination Certificate
2011-01-25
2011-01-25
Astorino, Michael C (Department: 3769)
Surgery
Diagnostic testing
C705S002000, C705S003000
Reexamination Certificate
active
07874984
ABSTRACT:
Novel methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug. Embodiments are provided in which the involved prescribers, pharmacies and patients are registered in one or more computer databases. Embodiments are also provided in which registered patients receive counseling information concerning the risks attendant to foetal exposure to the drug. Male patients and female patients who are not pregnant may, in certain circumstances, receive the drug.
REFERENCES:
patent: 5299121 (1994-03-01), Brill et al.
patent: 5594637 (1997-01-01), Eisenberg et al.
patent: 5619991 (1997-04-01), Sloane
patent: 5660176 (1997-08-01), Iliff
patent: 5758095 (1998-05-01), Albaum et al.
patent: 5832449 (1998-11-01), Cunningham
patent: 5845255 (1998-12-01), Mayaud
patent: 5974203 (1999-10-01), Tadokoro et al.
patent: 6014631 (2000-01-01), Teagarden et al.
patent: 6045501 (2000-04-01), Elsayed et al.
patent: 6055507 (2000-04-01), Cunningham
patent: 6063026 (2000-05-01), Schauss et al.
patent: 6128620 (2000-10-01), Pissanos et al.
patent: 6131090 (2000-10-01), Basso, Jr. et al.
patent: 6202923 (2001-03-01), Bayer et al.
patent: 6315720 (2001-11-01), Williams et al.
patent: 6561976 (2003-05-01), Elsayed et al.
patent: 6561977 (2003-05-01), Williams et al.
patent: 6755784 (2004-06-01), Williams et al.
patent: 6767326 (2004-07-01), Elsayed et al.
patent: 6869399 (2005-03-01), Williams et al.
patent: 6908432 (2005-06-01), Elsayed et al.
patent: 2006/0129433 (2006-06-01), Koneru
patent: 2 352 619 (2003-01-01), None
patent: WO 96/13790 (1996-05-01), None
patent: WO 98/13783 (1998-04-01), None
patent: WO 98/58338 (1998-12-01), None
patent: WO 99/10829 (1999-03-01), None
patent: WO 00/51053 (2000-08-01), None
patent: WO 02/35440 (2002-05-01), None
Transcript, Thalidomide: Potential Benefits and Risks, an open public scientific workshop, Sponsored by National Institutes of Health, Food and Drug Administration, Centers for Disease Control and Prevention, Sep. 9, 1997.
Bakken, K., et al., “Local monitoring center for clozapine therapy: quality assurance of drug treatment in a group of psychiatric patients,”Tidsskr Nor Laegeforen nr., 1998, 118, 1076-1078 (English abstract middle of p. 1076).
Bastani, B., et al., “Development of the clozaril patient management system,”Psychopharmacology, 1989, 99, S122-S125.
Behm, G.A., Jr., No Title,Am. Pharmacy 13thAPhA Annual Meeting Highlights, 1990, NS30(6), p. 7.
Bender, K.J., “FDA approves reduced clozapine monitoring; increased patient access versus increased risk,”Psychiatric Times, 1998, vol. XV, Issue 5, p. 13.
Black, L.L., et al., “A centralized system for monitoring clozapine use in British Columbia,”Psychiatric Services, 1996, 47(1), 81-83.
Freeman, D.J., et al., “Will routine therapeutic drug monitoring have a place in clozapine therapy?,”Clinical Pharmacokinetics, 1997, 32(2), 93-100.
Honigfeld, G., et al., “Reducing clozapine-related morbidity and mortality: 5 years of experience with the clozaril national registry,”J. Clin. Psychiatry, 1998, 59(Suppl. 3), 3-7.
Kumar, V., “Clozaril monitoring systems, registry data and analyses,” Presentation,Novartis, 2002, 44 pages.
Lieberman, J.A., et al., “A report of clozapine—induced agranulocytosis in the United States (Incidence and risk factors),”Drug Safety, Proceedings of a symposium held in London, 1991, Hoffbrand, A.V, et al. (Eds.), 1-2.
Love, D.J., et al., “Computerized relational database for monitoring clozapine therapy,”Am. J. Hosp. Pharm., 1993, 1657-1662.
Martin, S., “APhA says plan continues to interfere with pharmacists' practice prerogatives,”Am. Pharmacy, 1991, NS31(5), 30-31.
Mordue, H.W., “Rational approach to clozaril distribution,”Am. Pharmacy, 1990, NS30(6), p. 7.
Oyesanmi, O., et al., “Hematologic side effects of psychotropics,”Psychosomatics, 1999, 40, 414-421.
Peck, C.C., et al., “FDA's position on the clozaril patient management system,”Hospital&Community Psychiatry, 1990, 41(8), 876-877.
Uhl, K. et al., “Thalidomide Use in the US: Experience with Pregnancy Testing in the S.T.E.P.S.® Programme,”Drug Safety, 2006, 29(4), 321-329.
Thalomid information from Drugs.com [online], Drugs.com, Jun. 22, 2006 [retrieved on Feb. 1, 2008], Retrieved from the internet: <URL: http://www.drugs.com/thalomid.html>.
Medical Marketing&Media, “Managing a product under attack: a firsthand report on Clozaril: Interview with Sandoz Ltd.'s director of product marketing, Barbara Rosengren and assistant director Gilbert Honigfeld,” Sep. 20, 1991,vol. 26, No. 10, p. 6.
Pastuszak, A. et al., “Use of the Retinoid Pregnancy Prevention Program in Canada: Patterns of Contraception Use in Women Treated With Isotretinoin and Etretinate,”Reproductive Toxicology, 1994, 8(1), 63-68.
Sittig, D. F. et al., “Computer-based Physician Order Entry: The state of the Art,”J. Amer. Med. Inform. Assoc., Mar./Apr. 1994, 1(2), 108-123.
Mitchell, A. A. et al., “A Pregnancy-Prevention Program in Women of Childbearing Age Receiving Isotretinoin,”N. Engl. J. Med., Jul. 13, 1995, 333(2), 101-106.
Trussell, J., “Contraceptive Efficacy,”Arch. Dermatol., Sep. 1995, 131, 1064-1068.
Honigfeld, G., “Effects of the Clozapine National Registry System on Incidence of Deaths Related to Agranulocytosis,”Psychiatric Services, Jan. 1996, 47(1), 52-56.
“Thalidomide protocols and patient materials designed by FDA for studies without commercial sponsors,” “The Pink Sheet”, Nov. 18, 1996, 58(047), p. T&G-4.
Physician's Desk Reference, 1997, pp. 2252-2254, 2377-2380.
FDA's Forty-Seventh Meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee, Sep. 4-5, 1997.
Thalidomide: Potential Benefits and Risks. An Open Public Scientific Workshop, Program and Abstracts, Sep. 9-10, 1997.
Thalidomide: Potential Benefits and Risks. An Open Public Scientific Workshop, Transcript: NIH Testimony from Sep. 9, 1997: http://www.fda.gov/oashi/patrep
ih99.html.
Thalidomide: Potential Benefits and Risks. An Open Public Scientific Workshop, Transcript: NIH Testimony from Sep. 10, 1997: http://www.fda.gov/oashi/patrep
ih910.html.
Janet Woodcock, Director, Center for Drug Evaluation and Research, “Supervisory Review of NDA 20-785,” Jul. 7, 1998.
“Hoechst Arava Pregnancy Registry Recommended to Track Teratogenicity,” “The Pink Sheet”, Aug. 17, 1998, vol. 60, No. 033, p. 23.
Reference Guide “Thalidomid™ (thalidomide): Clinical Information and Prescribing Guidelines,” Celgene Corporation, Sep. 1998.
Bates, D. W. et al., “Effect of Computerized Physician Order Entry and a Team Intervention on Prevention of Serious Medication Errors,”JAMA, Oct. 21, 1998, 280(15), 1311-1316.
System for Thalidomide Education and Prescribing Safety, “Thalidomid™ (thalidomide): Balancing the Benefits and the Risks,” Celgene Corporation, Nov. 1998.
Zeldis, J. B. et al., “S.T.E.P.S.™: A Comprehensive Program for Controlling and Monitoring Access to Thalidomide,”Frontiers in Fetal Health: A Global Perspective, The Fetal Centre at the Hospital for Sick Children, Toronto, Canada, vol. 1, No. 2, Aug. 1999.
Roche's Press Release Regarding Pregnancy Prevention Program for Women for Women on Accutane, Oct. 31, 2001.
Villahermosa, L. G. et al., “A Randomized, Double-Blind, Double-Dummy, Controlled Dose Comparison of Thalidomide for Treatment of Erythema Nodosum Leprosum,”Am. J. Trop. Med. Hyg., 2005, 72(5), 518-526.
Uhl, K. et al., “Thalidomide Use in the US: Experience with Pregnancy Testing in the S.T.E.P.S.® Programme,”Drug Safety, 2006, 29(4), 321-329.
“About the CNR,” Website Printout: https://www.clozarilcare.com/care/NewUsrReqPersona
Elsayed Marc
Williams Bruce
Astorino Michael C
Celgene Corporation
Woodcock & Washburn LLP
LandOfFree
Methods for delivering a drug to a patient while preventing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for delivering a drug to a patient while preventing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for delivering a drug to a patient while preventing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2633793